利福霉素类与抗凝抗血小板药的药物相互作用系统综述
该系统综述评估利福霉素类与抗凝抗血小板药联用对药代动力学、实验室指标及临床安全有效性的影响,共纳入29项研究。利福平与华法林联用使华法林AUC降低15%-74%,需将华法林剂量增至用利福平前的3-5倍以维持凝血参数在治疗范围;DOAC的AUC降低20%-67%。多数联用存在问题,需进一步研究利福布汀或利福喷丁能否作为安全替代。
要点
- 利福平与华法林联用需将华法林剂量增至用利福平前的3-5倍以维持凝血参数在治疗范围。
- 利福平与DOAC联用使DOAC的AUC降低20%-67%,因药物和利福霉素种类而异。
- 氯吡格雷活性代谢物与利福平联用时显著增加,普拉格雷基本不受影响,替格瑞洛则降低。
核心结论
- 多数抗凝抗血小板药与利福平联用存在问题,需进一步研究利福布汀或利福喷丁能否作为安全替代。
研究设计与样本
- 遵循PRISMA指南的系统综述,检索PubMed、Embase和Web of Science数据库自建库至2021年8月的英文报告。
- 共纳入29项研究,其中17项研究华法林、8项研究DOAC、4项研究抗血小板药;28项联用利福平,1项联用利福布汀。
主要发现
- 利福平与华法林联用使华法林AUC降低15%-74%,因华法林异构体和研究而异。
- 维持凝血参数在治疗范围需将华法林剂量增至用利福平前的3-5倍。
- DOAC的AUC降低20%-67%,因具体药物及利福平与利福布汀而异。
- 氯吡格雷活性代谢物与利福平联用时显著增加,普拉格雷基本不受影响,替格瑞洛则降低。
关键数值与推荐
- 利福平与华法林联用使华法林AUC降低15%-74%。
- 维持凝血参数在治疗范围需将华法林剂量增至用利福平前的3-5倍。
- 利福平与DOAC联用使DOAC的AUC降低20%-67%。
临床怎么用
- 利福平与华法林联用时应增加华法林剂量并密切监测凝血参数。
- 利福平与DOAC联用可能需调整DOAC剂量或选择替代抗凝方案。
- 利福平与氯吡格雷联用可能增加活性代谢物,与替格瑞洛联用则降低其暴露。
局限性
- 14项研究在健康志愿者中报告药代动力学或实验室指标,临床结局数据有限。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Rifamycins (rifampin, rifabutin, and rifapentine) play an essential role in the treatment of mycobacterial and some nonmycobacterial infections. They also induce the activity of various drug transporting and metabolizing enzymes, which can impact the concentrations and efficacy of substrates. Many anticoagulant and antiplatelet (AC/AP) agents are substrates of these enzymes and have narrow therapeutic indices, leading to risks of thrombosis or bleeding when coadministered with rifamycins. The objective of this systematic review was to evaluate the effects on AC/AP pharmacokinetics, laboratory markers, and clinical safety and efficacy of combined use with rifamycins. A systematic review following the Preferred Reporting Items for Systematic Reviews and Meta-analyses guidance was performed. The PubMed, Embase, and Web of Science databases were queried for English-language reports on combination use of rifamycins and AC/AP agents from database inception through August 2021. The 29 studies identified examined warfarin (n = 17), direct oral anticoagulants (DOACs) (n = 8), and antiplatelet agents (n = 4) combined with rifampin (n = 28) or rifabutin (n = 1). Eleven studies were case reports or small case series; 14 reported on pharmacokinetic or laboratory markers in healthy volunteers. Rifampin-warfarin combinations led to reductions in warfarin area under the curve (AUC) of 15%-74%, with variability by warfarin isomer and study. Warfarin dose increases of up to 3-5 times prerifampin doses were required to maintain coagulation parameters in the therapeutic range. DOAC AUCs were decreased by 20%-67%, with variability by individual agent and with rifampin versus rifabutin. The active metabolite of clopidogrel increased substantially with rifampin coadministration, whereas prasugrel was largely unaffected and ticagrelor saw decreases. Our review suggests most combinations of AC/AP agents and rifampin are problematic. Further studies are required to determine whether rifabutin or rifapentine could be safe alternatives for coadministration with AC/AP drugs.
引用
- MacDougall C, Canonica T, Keh C, et al. Systematic review of drug-drug interactions between rifamycins and anticoagulant and antiplatelet agents and considerations for management. Pharmacotherapy. 2022. PMID: 35152432. doi:10.1002/phar.2672
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。